title: Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer.
abstract: Based on the results of combined data from three North American Phase II studies, a randomised Phase II study in the same patient population was performed, using combination chemotherapy with estramustine phosphate (EMP) and vinblastine (VBL) in hormone refractory prostate cancer patients. In all, 92 patients were randomised into a Phase II study of oral EMP (10 mg kg day continuously) or oral EMP in combination with intravenous VBL (4 mg m(2) week for 6 weeks, followed by 2 weeks rest). The end points were toxicity and PSA response in both groups, with the option to continue the trial as a Phase III study with time to progression and survival as end points, if sufficient responses were observed. Toxicity was unexpectedly high in both treatment arms and led to treatment withdrawal or refusal in 49% of all patients, predominantly already during the first treatment cycle. The mean treatment duration was 10 and 14 weeks, median time to PSA progression was 27.2 and 30.8 weeks, median survival time was 44 and 50.9 weeks, and PSA response rate was only 24.6 and 28.9% in the EMP/VBL and EMP arms, respectively. There was no correlation between PSA response and survival. While the PSA response in the patients tested was less than half that recorded in the North American studies, the toxicity of EMP monotherapy or in combination with VBL was much higher than expected. Further research on more effective and less toxic treatment strategies for hormone refractory prostate cancer is mandatory.
authors.affiliation: Department of Urology, Rudolfstiftung, Juchgasse 25, Vienna A 1030, Austria. walter.albrecht@kar.magwien.gv.at
authors.forename: W
authors.initials: W
authors.lastname: Albrecht
authors.forename: H
authors.initials: H
authors.lastname: Van Poppel
authors.forename: S
authors.initials: S
authors.lastname: Horenblas
authors.forename: G
authors.initials: G
authors.lastname: Mickisch
authors.forename: A
authors.initials: A
authors.lastname: Horwich
authors.forename: V
authors.initials: V
authors.lastname: Serretta
authors.forename: G
authors.initials: G
authors.lastname: Casetta
authors.forename: J M
authors.initials: JM
authors.lastname: Maréchal
authors.forename: W G
authors.initials: WG
authors.lastname: Jones
authors.forename: S
authors.initials: S
authors.lastname: Kalman
authors.forename: R
authors.initials: R
authors.lastname: Sylvester
mesh_terms: D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D004961:Estramustine; D014747:Vinblastine; D017430:Prostate-Specific Antigen